Navidea Biopharma (NAVB) Tops Q3 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $1.54 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Goldman Sachs Upgrades SK Innovation Co Ltd (096770:KS) to Neutral
• Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold